Key result
This review summarizes the current state of knowledge on the innate and adaptive immune response to cytomegalovirus following solid organ transplantation.
This review summarizes current knowledge on the immune response to CMV in solid organ transplant recipients, highlighting the need for novel prevention strategies.
CMV persists as a major threat in SOT despite advances; leaves open optimal prevention strategies for D+/R- recipients.
Despite advances in immunosuppression and antiviral therapy, CMV continues to be a significant opportunistic pathogen adversely affecting the outcome of solid organ transplantation (SOT) recipients. While a significant proportion of CMV disease is caused by reactivation of latent virus, the risk is highest among CMV donor+ and recipient- SOT patients. CMV is responsible for both direct (e.g., pneumonitis, colitis) and indirect (e.g., rejection, atherosclerosis) morbidity and mortality. Healthy CMV-seropositive individuals have a high frequency of CMV-specific CD4(+) and CD8(+) T cells that provide immune protection by limiting CMV reactivation and replication. Changes to the innate and adaptive immune system from immunosuppressive therapy following SOT contribute to CMV disease pathogenesis. CMV disease after SOT is associated with poorer outcomes, thus novel strategies to prevent it are an area of active research. In this article, we review the current state of knowledge on the immune response to CMV following SOT.
No takes yet. Share an insight, caveat, or question.
Watkins et al. (2012) conducted a review in Cytomegalovirus (CMV) infection in solid organ transplant recipients. This review summarizes the current state of knowledge on the innate and adaptive immune response to cytomegalovirus following solid organ transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: